Josh Nathan-Kazis

The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.

Teva and its partner Sanofi said that 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical remission, compared with 20.5% who received a placebo.

The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss market.

Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.

The company’s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.

The FDA said will continue to allow certain compounders to keep making compounded tirzepatide for some time.

The FDA said will continue to allow certain compounders to keep making compounded tirzepatide for some time.

Henrik Wulff, the man in charge of product supply at Novo Nordisk just spent $11 billion to try to fill an ocean. Novo has handed Wulff one of the most complex jobs in all of pharmaceuticals. Novo and its competitor Eli Lilly have gone to greater and greater lengths to speed their GLP-1 output, as they battle each other and the increasingly aggressive telehealth industry, which is selling large quantities of legal GLP-1 knockoffs.

In This Article LLY VKTX GPCR

For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the drug. Patients lost only 22.7% of their body weight, on average, after about a year and a half.